Generics

Solifenacin succinate tablets had a market value of roughly $942.7 million for the 12 month period ended March 2019, according to IQVIA.

The AAM and the Biosimilars Council continue to urge the FDA to foster the development of biosimilar insulins.

The U.S. healthcare system has saved $2 trillion in the last decade due to low-cost generics, according to a new AAM report.

Zydus Cadila's chlorthalidone tablets will be available in two dosage strengths.

Olopatadine hydrochloride ophthalmic solution, 0.2%, had a market value of $62 million for the 12 months ending December 2018, according to IQVIA data.

The Food and Drug Administration is providing final guidance on the pathway for “interchangeable” biologics, which may be substituted without the involvement of the prescriber.

Cubicin for injection had a market value of roughly $640.8 million for the most recent 12 months ended in March 2019, according to IQVIA data.

The Association for Accessible Medicines has sent two letters to Capital Hill in advance of House consideration of H.R. 987.